Coronavirus
-
Coming soon: The 'Vaccine Passport'
The challenge however is in creating a document or app that is accepted around the world, that protects privacy and is accessible to people regardless of their wealth or access to smartphones
-
Israel's vaccine success unleashes a debate on Palestinian inequities
Israel quickly became the world leader in vaccinating its population against Covid-19, but almost all Palestinian residents of the occupied West Bank are still waiting for their first doses of the inoculation
-
One year, 400,000 Coronavirus deaths: How the US guaranteed its own failure
The situation has turned dire just as the Trump administration, in its final days, begins to see the fruits of perhaps its biggest coronavirus success, the Operation Warp Speed vaccine program
-
Most major economies are shrinking. Not China's
The Chinese economy rose 2.3% last year, the country’s National Bureau of Statistics announced Monday in Beijing
-
India's Covid-19 vaccine: A look at the blueprint of the rollout plan starting Jan 13
As India conducts the second dry run for Covid-19 vaccine rollouts today, we look at the framework of last-mile vaccine delivery, which includes real-time, remote temperature monitoring and capturing vaccination data in an electronic database
-
Warning of shortages, researchers look to stretch vaccine supply
Scientists at the National Institutes of Health and drugmaker Moderna are analyzing data to see if they can double the supply of the company's coronavirus vaccine by cutting doses in half
-
'A slap in the face': The pandemic disrupts young oil careers
With fewer people commuting and traveling, the oil and gas industry has taken a punishing blow, and Oil companies have laid off more than 100,000 workers
-
India approves Oxford-AstraZeneca COVID-19 vaccine and one other
Criticism about the lack of clarity on the data that the regulator examined came swiftly after the two vaccines were authorized for emergency use
-
A Chinese COVID-19 vaccine has proved effective, its maker says
Sinopharm, a state-controlled firm said that a vaccine candidate made by its Beijing Institute of Biological Products arm had an efficacy rate of 79%
-
One more vaccine side effect: Global economic inequality
Wealthy nations in Europe and North America have secured the bulk of limited stocks of vaccines, positioning themselves for starkly improved economic fortunes
-
What the vaccine side effects feel like, according to those who've gotten it
13 percent of the recipients aged 18 to 55 had a bad headache after taking the Pfizer vaccine while 16 percent of those who took the vaccine, made by Moderna, had a reaction strong enough to prevent them from going about their daily routine